The Israeli biotechnology company has claimed this week that its scientists have developed a cancer cure and made it available for a year, attracting international attention – and a healthy dose of skepticism.
President of Accelerated Evolution Biotechnologies Ltd. (AEBi), founded in 2000 by ITEK Technological Incubator ITEM Weizmann, told the Jerusalem Post that cancer treatment company will be effective from the first day, it will take several weeks and will not have or have minimal side effects at a significantly lower price than most other treatments on the market. "
"We believe we will offer a full cancer drug for a year," Dan Aridor told the Israeli daily, adding that "our solution will be both generic and personal."
SEE ALSO: 7 Recent Israeli penetrations in cancer research and detection
New developments have picked up numerous media releases in Israel and around the world. Meanwhile, AEBi did not provide evidence of its findings and claimed it had no means of publishing any reviewed scientific journals.
However, the company says that developed therapy, MuTaTo (multi-target toxin), a new, multiple attack on cancer cells using peptides that showed "consistent and repeatable" results in "the first research experiment of mice that inhibited the human cancer cell." and has no effect on healthy mice cells, with several in vitro experiments, "reported Jerusalem Post.
Red flags everywhere
Dr. Victoria Forster, a Cancer Researcher and Postdoctoral Researcher at the SickKids in Toronto, Canada, wrote in Forbes' article that the first "red flag" was a statement by AEB's executive director Ilana Morada for what treatment could be achieved .
"Instead of attacking receptors one by one, attacking receptors three at a time – even cancer can not mutate three receptors at the same time," said Morad Jerusalem Post.
"It's categorically untruthful," Forster wrote. "The cancer may have from one to several tens of thousands of mutations of DNA in their genome, and many of them are" receptors "to which Morad is unclear. The key principle of using multiple chemotherapeutic agents is to go to cancer cells in several ways to reduce However, many cancers are resistant to these treatment protocols, so Morad's logic here is extremely unsafe. "
Further, the Israeli affirmation that her treatment will affect all kinds of cancer is also "a huge red flag," she said.
"There are more than 200 different types of cancer and within these, several other subtypes. To have one, universal "cancer drug," which overwhelms all those differences, is unlikely, "Forster accused.
An Australian cancer researcher has gone a step further, accusing the company of "selling unicorn" and inviting him to "suck for making such cruel and misleading claims."
In a proud review of popular culture, Dr. Darren Saunders, biologist, said that treatment of AEBs "is basically the Fyre Festival of Cancer Treatment". The Fyre Festival is widely promoted as a "luxury music festival" to be held in the Bahamas in 2017 and was soon exposed to fraud. There are currently two documentaries about the saga.
"Irresponsible and even cruel" claims
Starker's warnings and direct convictions did not lag far behind.
Dr. J. Leonard Lichtenfeld, the deputy chief physician for the Cancer Society's National Office, wrote in a blog post titled "Cure for cancer? Not so fast "while Israeli scientists" worked with an interesting approach to hampering the ability of cancer cells to function ", there were very limited information that was" not published in the scientific literature where they would be subject to review, support, and / or criticism by high-quality people. "
He further noted that AEBi's initial experiment on mice in clinical trials "is not well-established experimentation program that could better define how it works – and may not work – as it moves from a laboratory bench to the clinic."
"The gap between a successful mouse experiment and the effective, useful application of exciting laboratory concepts in helping cancer patients on the bed is actually a long and frustrating journey, filled with unpredictable and unexpected obstacles," Lichtenfeld wrote that treatment would be available for a year.
Dr. Benjamin Neel, professor of medicine at NYU Medical School and Director of Laura Cancer and Isaac Perlmutter in New York, told ABC11 News that "although there is always something new, it is unlikely that the company has developed something to cure all kinds cancer within a year. I mean, that's just not convincing. "
"They did not give us any details of the access, but they make it extraordinary, and in my capacity, very irresponsible and even cruel (for cancer patients) to cure cancer in the year," Neel Forbes .
"We never have to say never in science, but I guess it's unlikely we'll see a magical shotgun. We do not have just one magic bullet for infectious diseases – different infections require different antibiotics, and even then resistance to antibiotics is developed. Cancer is not a single disease – its multiple diseases, each of which causes different combinations of genetic changes within different types of target cells. We already know how to cure many forms of cancer, and they are all different, "he said.
SEE ALSO: Israeli researchers say they can reschedule cancer cells back to their country before cancer
As health professionals and researchers who hear about "new cancer drugs" with little or no evidence and "asking questions about everything from baking soda to lemon that cures cancer, often from desperate cancer patients or their families," it did not a new scenario, wrote Forster. She said that it is a "heartbreaking" view of cancer patients who are turning to financing "collecting money for these unsophisticated cancer drugs".
"Our hopes are always on the side of new discoveries in diagnosing and treating cancer," wrote Lichtenfeld, but it should also be very cautious.
Morad had in the meantime defended the company's findings in the Times of Israel interview, saying the company wanted to focus on research rather than funding the publication of its findings.
– If we are a big company with a lot of resources, that [publication] it would be the first thing we could do, "he said. – If I have $ 100,000 on what I spend? Improve research and find more and more targeted peptides, or many experiments to write articles? What would you do if you had to choose?
Blue-white cancer study
Israeli scientists and researchers have been at the forefront of extensive cancer and cancer treatment over the last decades.
SEE ALSO: Pioneering cancer therapy developed by the Israeli MedTech for clinical trials
Israeli universities, medical centers, hospitals and laboratories have taken a leading role in developing innovative care plans and undertake sophisticated research to enhance understanding and knowledge of cancer for which there is no known drug.
Numerous Israeli biotechnological startups have also been on innovative early detection solutions, clinical pathology and therapy systems.